Placental glycoprotein hormone and LH-receptor agonist
HCG is a placental hormone that acts much like luteinizing hormone. Approved products are used in carefully defined fertility and endocrine settings, including triggering final egg maturation or ovulation and selected male hypogonadotropic hypogonadism. People also discuss it alongside testosterone therapy, but the clearest study there is a short intratesticular-testosterone biomarker trial—not proof of maintained fertility. HCG is not a supported weight-loss or appetite-suppression treatment.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Approved fertility products, monitored reproductive programs, male hypogonadotropic-hypogonadism studies, pharmacology experiments, and negative obesity trials are available.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Effectiveness is well established for specific fertility and gonadotropin-deficiency settings, but product, route, population, and co-treatment determine what the evidence means.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Ovidrel is a recombinant, ready-to-use prefilled product used inside specialist-monitored fertility care. Its microgram amount, device, pharmacokinetics, and outcomes cannot be converted into instructions for urinary-derived, compounded, or research-market hCG. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
What the evidence says
Multiple approved reproductive-endocrine indications supported by product-specific controlled programs and decades of condition-specific human research.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Long-term benefit and safety of off-label hCG alongside testosterone, comparative fertility strategies, and the identity and handling of nonapproved products.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
Spermatogenesis occurred in 84.6%, 69.2%, and 75% across the three strategies, with no significant difference. The triple-therapy strategy used less hCG at spermatogenesis and reported better quality-of-life measures.
The approved Ovidrel program established product-specific effectiveness for final follicular maturation and ovulation induction. In the label's ovulation-induction study, 91.9% ovulated and 22% had a clinical pregnancy; multiple births occurred among reported live births.
FDA states that hCG is not approved for weight loss and that controlled evidence does not show added weight loss, reduced hunger, or improved fat distribution beyond calorie restriction.
Testosterone and symptom scores increased in all three groups over three months. Testosterone restoration did not differ significantly between the groups.
Testicular volume and testosterone increased, and 64% produced sperm. Larger starting testicular volume and no history of cryptorchidism predicted earlier sperm appearance; 19 of 34 men seeking fatherhood achieved partner pregnancy.
Administration and handling
Official products are not interchangeable. Pregnyl and Novarel are urinary-derived powders labeled for intramuscular use after reconstitution; Ovidrel is a recombinant single-use subcutaneous prefilled solution. Approved fertility treatment requires patient selection and monitoring, including ultrasound and estradiol where applicable. Published male studies used different condition-specific regimens, often with FSH or hMG and months of follow-up. Those protocols are evidence records, not a starter dose, cycle, testosterone add-on, fertility guarantee, or self-treatment plan.
Pregnyl's current label says to use only its provided solvent, add the label-specified volume, agitate gently without shaking, inspect the solution, refrigerate at 2–8°C after reconstitution, do not freeze, and discard after 60 days. Novarel's label gives a 30-day refrigerated window after reconstitution. Ovidrel is a single-use prefilled solution and is not reconstituted. These differences are why a generic hCG calculator cannot establish safe dilution, sterility, concentration, storage, or a beyond-use date for compounded or research products.
Primary-source ledger
2026-04-01 · PMID 41993983 · CTRI/2022/05/042795 · DOI 10.3389/fendo.2026.1777584
2025-03-01
2023-07-01
2023-05-01
2022-03-30
2018-11-01 · PMID 29772111 · DOI 10.1111/bju.14401
2016-03-01 · PMID 26945370 · DOI 10.1097/MD.0000000000002867
2005-05-01 · PMID 15713727 · DOI 10.1210/jc.2004-0802
1990-02-17 · PMID 2405506
1985-09-12 · PMID 3927163 · DOI 10.1056/NEJM198509123131102